XML 44 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2014
Segment Reporting [Abstract]  
Schedule of Financial Data for Business Segments
The financial data for the two business segments are as follows ($ amounts in thousands):

 
Three months ended
 
Nine months ended
 
September 30, 2014
 
September 30, 2013
 
September 30, 2014
 
September 30, 2013
Revenues:
 
 
 
 
 
 
 
Par Pharmaceutical
$
318,784

 
$
249,818

 
$
871,425

 
$
737,733

Strativa
17,333

 
17,503

 
49,182

 
53,453

Total revenues
$
336,117

 
$
267,321

 
$
920,607

 
$
791,186

 
 
 
 
 
 
 
 
Gross margin:
 
 
 
 
 
 
 
Par Pharmaceutical
$
129,845

 
$
69,506

 
$
297,374

 
$
175,502

Strativa
10,980

 
11,885

 
31,276

 
36,233

Total gross margin
$
140,825

 
$
81,391

 
$
328,650

 
$
211,735

 
 
 
 
 
 
 
 
Operating loss:
 
 
 
 
 
 
 
Par Pharmaceutical
$
(29,846
)
 
$
(18,352
)
 
$
(61,409
)
 
$
(19,169
)
Strativa
(3,029
)
 
(6,373
)
 
(23,148
)
 
(4,446
)
Total operating loss
$
(32,875
)
 
$
(24,725
)
 
$
(84,557
)
 
$
(23,615
)
Interest income
2

 
14

 
16

 
70

Interest expense
(27,690
)
 
(23,385
)
 
(80,656
)
 
(71,033
)
Loss on debt extinguishment
—

 
—

 
(3,989
)
 
(7,335
)
Other Income
500

 
—

 
500

 
—

Benefit for income taxes
(22,425
)
 
(18,797
)
 
(64,762
)
 
(36,077
)
Net loss
$
(37,638
)
 
$
(29,299
)
 
$
(103,924
)
 
$
(65,836
)
Schedule of Total Revenues of Top Selling Products
Total revenues of our top selling products were as follows ($ amounts in thousands):

 
Three months ended
 
Nine months ended
 
September 30, 2014
 
September 30, 2013
 
September 30, 2014
 
September 30, 2013
Product
 
 
 
 
 
 
 
Par Pharmaceutical
 
 
 
 
 
 
 
Budesonide (Entocort® EC)
$
32,065

 
$
54,952

 
$
107,680

 
$
150,382

Propafenone (Rythmol SR®)
18,858

 
19,423

 
55,235

 
53,919

Oxycodone (Oxycontin®)
18,334

 
—

 
18,334

 
—

Omega-3 acid ethyl esters (Lovaza®)
17,716

 
—

 
17,716

 
—

Bupropion ER (Wellbutrin®)
16,581

 
11,450

 
51,346

 
31,268

Divalproex (Depakote®)
10,849

 
26,343

 
46,765

 
20,116

Metoprolol succinate ER (Toprol-XL®)
9,312

 
12,277

 
35,525

 
45,206

Lamotrigine (Lamictal XR®)
8,789

 
11,079

 
29,185

 
41,725

Rizatriptan (Maxalt®)
3,760

 
5,283

 
7,555

 
42,296

Par Sterile Products
46,751

 
—

 
96,479

 
—

Other (1)
126,959

 
101,788

 
386,369

 
330,624

Other product related revenues (2)
8,810

 
7,223

 
19,236

 
22,197

Total Par Pharmaceutical Revenues
$
318,784

 
$
249,818

 
$
871,425

 
$
737,733

 
 
 
 
 
 
 
 
Strativa
 
 
 
 
 
 
 
Megace® ES
$
7,712

 
$
9,455

 
$
23,644

 
$
31,009

Nascobal® Nasal Spray
8,457

 
7,592

 
22,953

 
20,596

Other
(1
)
 
(398
)
 
(47
)
 
(877
)
Other product related revenues (2)
1,165

 
854

 
2,632

 
2,725

Total Strativa Revenues
$
17,333

 
$
17,503

 
$
49,182

 
$
53,453


(1)
The further detailing of revenues of the other approximately 85 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the nine-month periods ended September 30, 2014 and 2013.
(2)
Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.